Leadless CRT Product (WiSE)EBR's WiSE is a differentiated leadless endocardial left-ventricular pacing system addressing patients who cannot receive or don't respond to conventional CRT. That structural clinical niche creates durable product differentiation and the potential for sustained market share in heart failure device therapy.
Early Commercialization Traction & Gross MarginRevenue growth to ~1.7M in 2025 with ~30% gross margin signals early commercial adoption and attractive unit economics. If volume scales, these margins support improving gross profitability and operating leverage, making sustainable cash generation more attainable over the coming months as commercialization expands.
Positive Equity And Larger Asset BaseDespite losses, positive equity (~25.6M) and increased assets (~97.3M) provide a tangible balance-sheet buffer. This improves resilience versus immediate insolvency risk, supports ongoing R&D and commercialization spending, and extends runway while management executes on scaling the WiSE system.